RENOVORX, INC. Net Fee Amt
RENOVORX, INC. (RNXT) had Net Fee Amt of $262.97 as of 2026-06-30, per its S-8 filed 2026-06-30.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-30
- 2026-06-30: Net Fee Amt $262.97.
- 2026-04-16: Net Fee Amt $2.79K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-30 | $262.97 S-8 · filed 2026-06-30 |
| 2026-04-16 | $2.79K S-3 · filed 2026-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |